Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O15232
UPID:
MATN3_HUMAN
Alternative names:
-
Alternative UPACC:
O15232; B2CPU0; Q4ZG02
Background:
Matrilin-3, encoded by the gene with accession number O15232, is a pivotal component of the extracellular matrix in cartilage. It plays a crucial role in the formation of extracellular filamentous networks, essential for maintaining the structural integrity and function of cartilage.
Therapeutic significance:
The protein is implicated in several skeletal disorders, including Multiple epiphyseal dysplasia 5, characterized by irregular ossification and early-onset osteoarthritis, and Spondyloepimetaphyseal dysplasia, Borochowitz-Cormier-Daire type, marked by disproportionate dwarfism and skeletal abnormalities. Additionally, it is associated with Osteoarthritis 2, a degenerative joint disease. Understanding the role of Matrilin-3 could open doors to potential therapeutic strategies for these conditions.